Science loves control because reality is badly behaved. A clinical trial can standardize dose, screening, timing, environment and measurement. That is precisely why clinical trials are useful. They reduce the number of things that can explain an outcome. Most psychedelic use, unfortunately for tidy diagrams, does not occur inside a clinical trial. That gap is the premise of a new…
Remove the mushroom. Now remove the third eye, the mandala, the melting clock, the neon skeleton, the sacred geometry and the little alien who appears to know your browser history. Is the artwork still psychedelic? If the answer is no, you may have been looking at iconography rather than visual experience. There is nothing wrong with mushrooms. We are fond…
Psychedelic neuroscience has accumulated a collection of irresistible phrases: increased entropy, network disintegration, flattened landscapes, relaxed beliefs, criticality. They are useful. They are also extremely easy to turn into the scientific equivalent of a lava lamp. A major 2026 psilocybin study in Nature complicates one of the most popular simplifications: that the psychedelic brain is mainly becoming more disordered. The…
A psychedelic image is not a liquid you pour into different containers. Put the same artwork on a wall, across a moving body, around a three-dimensional object and on a glowing screen and you have changed more than the delivery system. You have changed scale, distance, motion, texture, light, context and the amount of control the viewer has over the…
Counterculture eventually develops a gift shop. That is not necessarily a criticism. It is simply one of culture’s more reliable metabolic processes. What begins in clubs, bedrooms, communes, print shops, ceremonies and places respectable people once warned their children about can eventually acquire archival gloves, wall text and timed-entry tickets. Psychedelic art is very much in that phase. The Royal…
Whenever psilocybin and Phase 3 appear in the same headline, the internet has a tendency to skip several steps. Phase 3 becomes “approved.” Approved becomes “legal.” Legal becomes “mushroom therapy is arriving next Tuesday.” Somewhere in the process, a clinical-development milestone turns into a small parade. What COMPASS Pathways has actually accomplished with COMP360 is significant enough that it does…
For a long time, psychedelic medicine had the luxury of being exciting. There were brain scans. Mystical experiences. Johns Hopkins studies. Michael Pollan. Breathless magazine covers. People who had taken mushrooms twice explaining consciousness to an entire dinner party. The central question was enormous and cinematic: Could psychedelics actually become medicine? Something interesting is happening in 2026. The question is…
Mushrooms have become impossible to keep in their lane. They were already food, poison, medicine, sacrament, decomposer, internet mascot and recurring guest star in the human imagination. Now they are increasingly material for contemporary art — not merely painted as cute caps in a forest, but used to think about networks, bodies, decay, communication and the uncomfortable possibility that the…
Psychedelics have spent decades being discussed as medicine, menace, sacrament, counterculture, investment thesis, and occasionally all five before lunch. In 2026 they acquired something less romantic but more consequential: a proper stack of regulatory paperwork. In July, the U.S. Food and Drug Administration finalized its guidance Psychedelic Drugs: Considerations for Clinical Investigations. The document is aimed at sponsors developing psychedelic…
If you listen closely to how people describe consciousness, you’ll notice something inconvenient. They don’t describe it as gradual. They don’t say, “One day I was 12% self-aware, then 18%, then 42%, and by 7th grade I finally reached full sentience.” Nobody remembers awareness as a gentle incline. Nobody tells the story like a slow sunrise. They describe it like…